CHMP recommends Boehringer's nintedanib for NSCLC

EMA's CHMP recommended approval of Vargatef nintedanib from Boehringer Ingelheim GmbH (Ingelheim, Germany) plus docetaxel to treat locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) with adenocarcinoma histology after failure of first-line chemotherapy.

CHMP said marketing authorization will include a pharmacovigilance plan. ...